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Abstract
Current treatments in multiple sclerosis (MS) are modulating the
inflammatory component of the disease, but no drugs are
currently available to repair lesions. Our study identifies in MS
patients the overexpression of Plexin-A1, the signalling receptor of
the oligodendrocyte inhibitor Semaphorin 3A. Using a novel type of
peptidic antagonist, we showed the possibility to counteract the
Sema3A inhibitory effect on oligodendrocyte migration and dif-
ferentiation in vitro when antagonizing Plexin-A1. The use of this
compound in vivo demonstrated a myelin protective effect as
shown with DTI-MRI and confirmed at the histological level in the
mouse cuprizone model of induced demyelination/remyelination.
This effect correlated with locomotor performances fully preserved
in chronically treated animals. The administration of the peptide
also showed protective effects, leading to a reduced severity of
demyelination in the context of experimental autoimmune
encephalitis (EAE). Hence, the disruption of the inhibitory microen-
vironmental molecular barriers allows normal myelinating cells to
exert their spontaneous remyelinating capacity. This opens
unprecedented therapeutic opportunity for patients suffering a
disease for which no curative options are yet available.
Keywords multiple sclerosis; myelination; oligodendrocyte; Plexin; Semaphorin
Subject Categories Pharmacology & Drug Discovery; Neuroscience
DOI 10.15252/emmm.201910378 | Received 26 January 2019 | Revised 23
August 2019 | Accepted 4 September 2019
EMBO Mol Med (2019) e10378
Introduction
The efficient propagation of electrical nerve impulses requires the
establishment of myelin sheaths around axons (Baumann & Pham-
Dinh, 2001). Multiple sclerosis (MS) is a disease affecting nerve
conduction as a consequence of myelin damages. Current treat-
ments of MS are not curative but only fighting the associated
inflammation without repairing myelin. The myelination process is
orchestrated by integrated cellular and molecular interactions
unravelling potential therapeutic strategies for remyelination (Mi
et al, 2007; Abu-Rub & Miller, 2018). During development, precur-
sors of oligodendrocytes (OL), the myelinating cells of the central
nervous system (CNS), use guidance cues to migrate towards their
target neuronal cells. Strikingly, this process is not restricted to
developmental phases but also occurs to a certain extent in the adult
brain. This is also the case in CNS-demyelinating diseases in which
partial spontaneous remyelination closely mimicking developmental
myelination is observed. Combinations of soluble factors and
membrane-bound cues are considered to create a specific molecular
environment dictating the precise recognition process leading to the
myelination of axons (Piaton et al, 2010). Among these factors regu-
lating the early phase of myelination, members of the Semaphorin
family have been shown to regulate OL precursor cell migration in
the optic nerve (Tsai & Miller, 2002) and inhibit adult OL process
outgrowth (Ricard et al, 2001). Strikingly, an analysis of human
multiple sclerosis sample tissues and the use of an experimental
model of demyelination revealed a clear spatio-temporal regulation
of Sema3A expression, thereby strengthening the idea of a role of
Semaphorins in myelination (Williams et al, 2007). However, little
is known about the expression of Semaphorin receptors in this
context. This is indeed a crucial issue because the biological func-
tions of Semaphorins are intimately linked to the composition of a
receptor complex associating various partners in order to trigger
appropriate growth-promoting or growth-inhibiting effects of Sema-
phorins (Derijck et al, 2010). Thus, we decided to investigate the
expression of Plexin-A1, one of the major Sema3A-transducing
receptors so far essentially described as a transducer of Sema3A
inhibiting signal in neurons (Pu¨schel, 2002) or for its role in the
immune system (O’Connor & Ting, 2008). We found that Plexin-A1
is overexpressed in the white matter of MS patients. Moreover, in
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mouse, only few CNP-positive OL expressed Plexin-A1. However,
we observed a sevenfold increase in CNP-positive OL in animals
exhibiting cuprizone-induced lesions. This was concomitant to local
deposition of Sema3A in the demyelinated regions. Moreover,
in vitro studies showed that blocking Plexin-A1 counteracted the
anti-migratory and anti-differentiation effect of Sema3A in oligoden-
drocytes. Hence, we showed that the administration of the Plexin-
A1 antagonist peptide MTP-PlexA1 improved myelin content and
locomotor activity in mice fed with cuprizone to induce demyeli-
nated lesions or in the context of experimental autoimmune
encephalomyelitis (EAE). Altogether, our results suggest a therapeu-
tic potential of inhibiting Plexin-A1 in myelin diseases such as multi-
ple sclerosis in which we found overexpression of Plexin-A1.
Results
Plexin-A1 is expressed in human oligodendrocytes
Previous studies showed the expression of Sema3A in MS lesions
(Williams et al, 2007) where it is supposed to contribute to the lack
of remyelination. We now examined whether OL express the
Sema3A signalling receptor Plexin-A1. To this end, we performed
immunocytochemical staining for Plexin-A1 on a human brain
tissue array. The results confirm previous data (Jacob et al, 2016),
showing neuronal expression of Plexin-A1 in several CNS locations,
but also demonstrate the expression in oligodendrocyte cells in the
white matter (Fig 1A). The global analysis of the tissue array
revealed a wide expression in several regions of the central nervous
system including the cortex, striatum or the spinal cord (data not
shown). To confirm the identity of Plexin-A1-expressing cells in the
white matter, we performed a CNP (30,50-cyclic nucleotide phospho-
diesterase) staining (pan-marker of oligodendrocytes) on the adja-
cent section of the tissue array. False colour coding of the
microphotographs allowed overlay of the two sections to exemplify
the co-expression of Plexin-A1 and CNP (Fig 1B).
Plexin-A1 is overexpressed in MS patients
In order to evaluate the Plexin-A1 level of expression in the context
of multiple sclerosis, we first performed data mining from published
gene array profiles using the GEO platform. The analysis of four
chronic plaques and two healthy controls (Han et al, 2012) revealed
an averaged 4.2-fold increase in Plexin-A1 mean expression (4.7-fold
increase in the median) and 3.2-fold increase in SEMA3A mean
expression (2.8-fold increase in the median) in the disease condition
(Appendix Fig S1). We next collected and analysed white matter
samples of 11 MS patients and nine healthy controls from the
Netherlands Brain Bank (see Appendix Table S1 for details). We
performed a Western blot analysis to evaluate Plexin-A1 content
and found a 2.3-fold increased expression in MS patients (Fig 2A
and B). The proportion of MS patients exhibiting such a twofold
increase in Plexin-A1 expression above the averaged expression
measured in healthy controls reached 45% of the patients (Fig 2C).
To further characterize this overexpression of Plexin-A1, we also
determined the number of CNP-Plexin-A1-positive cells by immuno-
cytochemistry conducted on fresh-frozen sections of the white
matter samples. As seen in Fig 2D and E, we found a threefold
increase in Plexin-A1-positive CNP-expressing cells in MS patients
compared to healthy controls. This suggested that Plexin-A1 may
represent an interesting target in the context of MS.
Plexin-A1 is overexpressed in OL in experimental
demyelination conditions
To address whether Plexin-A1 may be involved in demyelination/
remyelination conditions in the adult, we used the cuprizone model.
In this model, a demyelination/remyelination process is obtained by
feeding mice with 0.3% cuprizone (bis-cyclohexanone oxal-dihydra-
zone) for 4 weeks (acute demyelination phase) and normal diet for
2 weeks (initiation of remyelination) or 4 weeks (induction of total
remyelination; see Fig 3A for representative examples). Administra-
tion of 8-week cuprizone diet induces permanent demyelination as
described previously (Matsushima & Morell, 2001). We performed
double immunostaining for CNP and Plexin-A1 and determined at
the corpus callosum level the number of double-positive cells in the
different demyelination/remyelination status (Fig 3B). Only few OL
expressed Plexin-A1 in control conditions (normal diet, 5.3% of
CNP-positive OL). However, we found that Plexin-A1 was signifi-
cantly overexpressed in OL after 4-week cuprizone and 2-week
normal diet administration (37.8% of CNP-positive OL, ANOVA,
P = 0.0015; Fig 3C). Strikingly, Plexin-A1 expression was back to
control level after total recovery (4-week cuprizone + 4-week
normal diet), while it was not overexpressed in the 8-week cupri-
zone group (Fig 3C). Moreover, similar to what has been previously
described in human samples of multiple sclerosis (Williams et al,
2007), we also found that Sema3A expression transiently increased
in acute phases of cuprizone-induced demyelination (Fig 3D). The
overexpression of Sema3A was not uniform throughout the brain
but rather matched with cuprizone-induced lesion sites. This
suggested that a Sema3A/Plexin-A1 signalling is reactivated in the
adult in case of demyelination/remyelination process.
MTP-PlexA1 cancels Sema3A repulsive effect on
oligodendrocyte migration
Sema3A deposit inhibits OPC recruitment into MS lesions, explained
in part by Sema3A repulsive effect (Boyd et al, 2013). We first
addressed the involvement of Plexin-A1 in Sema3A signalling by
RNA interference. We obtained a significant 50% knockdown of
Plexin-A1 in Oli-neu cells as seen by immunocytochemistry and RT–
qPCR (Fig 4A). We used XCELLigence transwell chambers to moni-
tor 2% serum-induced chemotactic migration of the OPC cell line
Oli-neu during 8 h. Compared to control migration without Sema3A,
addition of 20 ng/ml Sema3A in the lower chamber decreased
migration of 37% of Oli-neu cells transfected with siRNA control.
Oli-neu cells transfected with siRNA targeting Plexin-A1 reached
95% of control migration (Fig 4B). This result confirmed the
requirement of Plexin-A1 to drive the inhibitory effect of Sema3A.
This lower expression was indeed sufficient to significantly decrease
the number of NRP1/Plexin-A1 dimers (a key step to trigger
semaphoring signalling) as determined by proximity ligation assay
(Fig 4C). We next used the recently developed peptidic antagonist
MTP-PlexA1. This peptide blocks receptor dimerization and signal-
ling by interfering with the transmembrane domain of Plexin-A1. It
has been successfully used in vitro to antagonize Plexin-A1
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signalling and cell migration, while it showed anti-tumour effect
in vivo (Jacob et al, 2016). Strikingly, the addition of MTP-PlexA1
induced a similar disruption of NRP1/Plexin-A1 dimers, thereby
confirming the inhibitory effect of the peptide (Fig 4D). Pre-incuba-
tion of the Oli-neu cells with MTP-PlexA1 (107 M) cancelled
Sema3A inhibitory effect by bringing migration up to the control
condition without Sema3A (Fig 4E). This effect of MTP-PlexA1 was
dose-dependent with a loss of efficacy from 109 M. Because of the
toxicity of the vehicle (LDS) alone on Oli-neu cells (data not
shown), we were not able to correctly evaluate higher concentra-
tions of the peptide. However, because a maximal effect was
obtained with 107 M we chose this concentration to define the
dose for in vivo evaluation consistently with previous studies (Jacob
et al, 2016).
MTP-PlexA1 favours oligodendrocyte differentiation in the
presence of Sema3A
Remyelination failure in MS lesions can result from the lack of OPC
recruitment as well as inhibition of OPC differentiation into mature
myelinating oligodendrocytes. Our second in vitro functional test
evaluated by RT–qPCR MTP-PlexA1 ability to increase a late oligo-
dendroglial marker (MBP) expression during neural stem cell (NSC)
differentiation. Plating of multipotent NSC onto PLO (poly-L-
ornithine) with low growth factor concentration induces their dif-
ferentiation into oligodendroglial, astrocytic glial and neural lineage.
By adding triiodothyronine hormone and ascorbic acid into differen-
tiation medium, we favoured oligodendroglial lineage. 100 ng/ml of
Sema3A reduced by twofold the expression of MBP mRNA after
A
B
Figure 1. Expression of Plexin-A1 in the human brain.
A Microphotographs showing the expression of Plexin-A1 on a section of human brain array in the cerebellum (ML: molecular layer; PC: Purkinje cell layer; GL: granular
layer; WM: white matter) and in the cortex. Oligodendrocytes in the white matter are expressing Plexin-A1. Scale bar = 10 lm.
B Immunostainings of Plexin-A1 and CNP (pan-oligodendrocyte marker) were conducted on adjacent sections of a human brain tissue array. Overlay of adjacent
sections with false colour coding confirms the oligodendrocytic identity of Plexin-A1-positive cells in the white matter. Arrowheads indicate examples of double-
stained oligodendrocytes. Scale bar = 10 lm.
ª 2019 The Authors EMBO Molecular Medicine e10378 | 2019 3 of 16
Fabien Binamé et al EMBO Molecular Medicine
4 days of differentiation, whereas concomitant treatment with
107 M of MTP-PlexA1 brings back MBP mRNA expression to 1.2-
fold of control condition without Sema3A (Fig 4F).
MTP-PlexA1 exhibits no toxicity in vivo
Because of the expression of Plexin-A1 in adult neurons (Jacob
et al, 2016), we had to check whether a chronic treatment with
MTP-PlexA1 could induce cognitive disabilities. We first evaluated
the locomotion capability of vehicle (LDS) and MTP-PlexA1-treated
animals that had received 1 lg/kg MTP-PlexA1 three times a week
for 4 weeks in an open-field task (Fig 5A). No difference was found
between the two groups, indicating that mice had the same explo-
ration capacity. We then investigated mouse anxiety with an
elevated plus maze (EPM) test. After quantification, groups exhib-
ited no significant difference in open-arm exploration,
A
B
D E
C
Figure 2. Expression of Plexin-A1 in multiple sclerosis patients vs. healthy controls.
A–C Plexin-A1 immunoblotting analysis of brain samples of multiple sclerosis patients (n = 11) and healthy controls (n = 9). (A) Western blot revealed with anti-Plexin-
A1 and stain-free method showing full protein content. (B) Relative expression normalized with full protein content (measured with stain-free method). Data are
presented as mean  SEM (Mann–Whitney, *P = 0.0167; n = 9 Ctrl and 11 MS patients). (C) Chi-square analysis of the proportion of patients with Plexin-A1
intensity > 2× mean control intensity.
D Representative microphotographs illustrating the expression of Plexin-A1 in CNP-positive OL in healthy control or MS white matter samples (Plexin-A1: green, CNP:
red). Arrowheads indicate oligodendrocytes (CNP) positive for Plexin-A1. Scale bar = 50 lm.
E Quantification of the number of the CNP/Plexin-A1-positive cells in the white matter of control (HC) or MS autopsies. Data are presented as mean  SEM
(unpaired t-test, ***P = 0.0035; n = 9 Ctrl and 11 MS patients).
Source data are available online for this figure.
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demonstrating that MTP-PlexA1 has no measurable effect on plus
maze-evaluated anxiety compared to vehicle (Fig 5B). Hence, we
assessed the hippocampal function integrity with a spatial recogni-
tion task. Here again, the object discrimination capacity (determined
through the recognition index) was identical in the two groups,
thereby demonstrating no impact of MTP-PlexA1 on mouse cogni-
tive functions (RI vehicle 0.36, RI MTP-PlexA1 0.35; Fig 5C and D).
To further address the innocuity of MTP-PlexA1, we also
performed a blood sample analysis on four vehicle and four MTP-
PlexA1-treated animals. White and red cell numeration showed no
difference. Kidney and hepatic functions were also equivalent in the
two groups (Appendix Table S2). This lack of toxicity offered the
possibility to test this administration schedule and dosing similar to
what was previously performed to treat tumours (Jacob et al, 2016)
in a model of demyelination to demonstrate the therapeutic poten-
tial of MTP-PlexA1.
MTP-PlexA1 rescues corpus callosum myelination in
demyelinating cuprizone murine model
To investigate the therapeutic potential of MTP-PlexA1, we followed
by MRI (DTI and T2WI) and histology the evolution of the white
A
B
C
D
Figure 3. Expression of Plexin-A1 and Sema3A in a model of adult demyelination–remyelination.
Histological analysis of CNP/Plexin-A1-positive cells in animal receiving 4-week cuprizone diet (acute demyelination phase), 4-week cuprizone diet followed by 2-week
normal diet (initiation of remyelination), 4-week cuprizone diet followed by 4-week normal diet (induction of total remyelination), and 8-week cuprizone diet (permanent
demyelination).
A Representative examples of demyelination plaques seen by osmium tetroxide impregnation (OsO4). Scale bar = 100 lm.
B Corresponding CNP/Plexin-A1 double staining showing Plexin-A1 expression in OL present at the lesion site. Scale bar = 10 lm.
C Quantification of the number of CNP/Plexin-A1-positive cells in the different experimental groups (w for weeks; data are presented as mean  SEM, n = 3 mice per
group in three independent experiments, 3–5 slices analysed per animal; ANOVA, **P = 0.0015).
D The expression of Sema3A is shown in adult brain at the level of hippocampus (sagittal sections) for control animals or animals receiving 4-week cuprizone diet
(acute demyelination phase), 4-week cuprizone diet followed by 2-week normal diet (initiation of remyelination), and 4-week cuprizone diet followed by 4-week
normal diet (induction of total remyelination). Scale bar = 1 mm.
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Figure 4. Inhibition of PlexA1 rescues Sema3A negative effect on migration and differentiation.
A Cells were transfected with siRNA control or siRNA PlexA1. Downregulation of Plexin-A1 was validated by immunofluorescence staining with anti-Plexin-A1 antibody
and by RT–qPCR analysis of Plexin-A1 mRNA expression normalized with GAPDH (data are presented as mean  SEM, n = 3; Mann–Whitney test, *P = 0.05). Scale
bar = 10 lm.
B Oli-neu cells were used for transfilter chemotaxis in response to 2% serum in the presence of Sema3A chemorepulsive (data are presented as mean  SEM, n = 4
independent experiments, 1-way ANOVA and Kruskal–Wallis test, *P = 0.0458).
C Proximity ligation assay analysis was performed to quantify NRP1/Plexin-A1 dimers per cell treated with indicated siRNA. Representative microphotographs
illustrating the different experimental conditions (data are presented as mean  SEM, n = 7, Mann–Whitney test, ***P = 0.0006). Scale bar = 10 lm.
D Proximity ligation assay analysis was performed to quantify NRP1/Plexin-A1 dimers per cell treated with vehicle or MTP-PlexA1. Representative microphotographs
illustrating the different experimental conditions (data are presented as mean  SEM, n = 8, Mann–Whitney test, **P < 0.0001). Scale bar = 10 lm.
E Oli-neu cells were used for transfilter chemotaxis in response to 2% serum in the presence of Sema3A chemorepulsive. Cells were pre-incubated with MTP-PlexA1 at
indicated concentrations or vehicle alone. Results are expressed as a percentage of positive control migration, i.e. migration with 2% serum and without Sema3A and
without chemoattractant (data are presented as mean  SEM, n = 3 independent experiments, ANOVA and Bonferroni’s multiple comparison test, **P = 0.0025,
***P = 0.0005).
F Expression of mature oligodendroglial marker MBP was analysed in murine neural stem cells (mNSCs) by RT–qPCR following 4 days of differentiation. Cells were
concomitantly treated with Sema3A and MTP-PlexA1 or vehicle. Results are expressed relatively to differentiated cells without treatment (data are presented as
mean  SEM, n = 3 independent experiments, ANOVA and Kruskal–Wallis test, *P = 0.0132).
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matter using the cuprizone-induced demyelination–remyelination
mouse model (Fig 6A). Averaged food intake monitoring confirmed
equal consumption of the cuprizone diets in all experimental
groups (Fig 6B). The analysis of T2WI signal intensity was used to
evaluate the level of inflammation (signing the existence of a toxic
effect of cuprizone), whereas DRAD (radial diffusion) signal
increase was used as a readout of demyelination (Klawiter et al,
2011). We found that the T2WI signal intensity was identical in the
two groups and the highest at W4 (123% of the baseline in control
and 124% MTP-PlexA1). The T2WI signal progressively decreased
in an equivalent manner for both groups at W6 and W8, thereby
confirming an equal cuprizone-induced demyelination process
(Fig 6C and D). To evaluate myelin damages, the t0 session was
used as a normalization value for each mouse. DRAD was averaged
to localize the demyelination areas in the corpus callosum (red to
yellow pixels; Fig 6E). From t0 to W4, DRAD does not differ signifi-
cantly from the baseline between vehicle (98%) and MTP-PlexA1
(97%). At W6, perturbation in the DRAD is observed for the vehi-
cle group (110%) but not for MTP-PlexA1 group (103%), which
almost stays at the baseline (Fig 6F). Strikingly, at W8, DRAD
signals are significantly higher (two-way ANOVA, P = 0.0196) in
the vehicle group (113%) than in the MTP-PlexA1 group (101%;
Fig 6F). To confirm the apparent gain in myelination in MTP-
PlexA1-treated mice, brains were collected at the end of the proto-
col to perform myelin histological staining. We performed Luxol
fast blue staining on 6-lm-thick sagittal brain slices (Fig 7A). We
analysed Luxol staining in the splenium and adjacent half of the
corpus callosum body, being the structures the most severely
demyelinated by cuprizone. We expressed staining intensity as a
percentage of healthy control. Mice fed 4 weeks with cuprizone
and injected with vehicle during the whole protocol exhibited 67%
of healthy control staining, whereas averaged staining of mice fed
4 weeks with cuprizone and treated with MTP-PlexA1 during the
whole protocol reaches 100% of healthy control staining (Fig 7A).
Histological pictures show a strong demyelination in the whole
analysed area of demyelinated control. In mice treated with vehicle,
intermediate demyelination appears and there was a clear lack of
myelin compaction inside the splenium, which is not observed in
healthy control and MTP-PlexA1-treated mice. This is further illus-
trated by immunostaining of PLP or staining with Fluoromyelin to
visualize myelin content at the different stages (Fig 7A). Hence, we
performed a proximity ligation assay on histological slices at the
level of the lesions in the corpus callosum and splenium (Fig 7B).
This analysis showed a dramatic loss of the number of NRP1/
Plexin-A1 dimers (50%, P = 0.0027) in treated animals compared
to controls. While demonstrating that a sufficient amount of the
peptide crossed the blood–brain barrier and reached the lesion
sites, this analysis provides a demonstration of the mechanism of
action of the peptide to exert its protective effects. Therefore, MTP-
PlexA1 appears to rescue myelin in corpus callosum to a normal
level despite cuprizone treatment by disrupting the signalling capa-
bility of Plexin-A1.
A B
C D
Figure 5. Cognitive toxicity assessment.
Mice were treated 4 weeks with vehicle or MTP-PlexA1 for behavioural tests.
A Determination of the global locomotion behaviour in the open-field task during 10 min (data are presented as mean  SEM, n = 10 mice per group, Mann–
Whitney test, n.s = not significant).
B Determination of the anxiety behaviour in the elevated plus maze with time spent in open arm during 10 min (data are presented as mean  SEM, n = 10 mice
per group, Mann–Whitney test, n.s = not significant).
C, D Spatial object recognition task measuring the novel object preference after training sessions. (C) Experimental procedure. (D) Recognition index = shifted object
time/total exploration time (data are presented as mean  SEM, n = 10 mice per group; Wilcoxon test, vehicle **P = 0.0020, MTP-PlexA1 **P = 0.0020).
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Analysis of functional recovery with CatWalk Assay
MTP-PlexA1 allowing myelin recovery at the histological level,
we looked for a positive effect in vivo on functional recovery.
Locomotion disorders represent a functional disability found in
MS patients and observed in demyelination models. We used
CatWalk assay to measure cuprizone feeding effect on mice gait
and to evaluate any curative potential of MTP-PlexA1. We estab-
lished a 10-week experiment where mice were fed 6 weeks with
cuprizone, then treated 4 weeks with MTP-PlexA1 or vehicle for
recovery. Cuprizone treatments induced alteration of temporal
and kinetic parameters. Because the results obtained with fore-
limbs (Fig 8) and hindlimbs (see Appendix Fig S2) are identical
at the same time points, they are described here without distinc-
tion. Stand Time, Swing and Step Cycle duration increased tran-
siently after 2 weeks of curative treatment in mice receiving
vehicle injections, whereas mice receiving MTP-PlexA1 presented
no alteration of these parameters (Fig 8A). There was a
A
C D
E F
B
Figure 6. Monitoring of cuprizone-induced demyelination.
A Schematic representation of the experimental protocol.
B Averaged cuprizone-complemented food intake per cage (data are presented as mean  SEM, n = 2 mice per cage).
C Inflammation levels visualized by T2 signal intensity in the corpus callosum normalized by t0 values in the control group (n = 5) and treated group (n = 4). Data are
presented as mean  SEM. Two-way ANOVA multiple comparisons, ***P < 0.001, **P < 0.01 between groups.
D Averaged T2 image obtained from signals in the vehicle and MTP-PlexA1 groups at W4, W6 and W8. Black arrows indicate inflammation at W4. Scale bar = 2.5 mm.
Mice received 4-week cuprizone diet followed by 4-week normal diet with concomitant vehicle or MTP-PlexA1 injections (vehicle group n = 5 and MTP-PlexA1 group
n = 4).
E B1 (rostral side) to B3 (caudal side) correspond to part of the body of the corpus callosum. First line of each group is an average T2 image of the group at W8. Second
line is the averaged DRAD maps obtained for each experimental group. Coloured pixels correspond to areas with a DRAD ratio W8/t0 between 1.1 and 2
corresponding to myelin loss. Scale bar = 2.5 mm.
F DRAD MRI signal determined in the posterior half of the corpus callosum normalized by t0 values. Signal over 100% are correlated with myelin signal loss. Data are
presented as mean  SEM, vehicle n = 5, MTP-PlexA1 n = 4. Groups are significantly different at W8 (ANOVA, *P = 0.0196).
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correlated significant Swing Speed decrease in mice receiving
vehicle at 2 weeks of recovery (Fig 8B). No significant alteration
occurred in Stride Length (Fig 8B). Therefore, 6 weeks of cupri-
zone feeding induced a transitory locomotor disorder, which
appearance is prevented by MTP-PlexA1. Increased Stand Time
indicated a longer postural phase, whereas increased Swing Dura-
tion without longer Stride Length indicated a slower and less
effective propulsion phase. This altered propulsion could have
different origins such as ataxia, muscular asthenia or spasticity,
reflecting a large impact of cuprizone counteracted by a protec-
tive effect of MTP-PlexA1 treatment.
MTP-PlexA1 exhibits protective effect in demyelinating EAE
murine model
We extended our therapeutic approach to the EAE mouse model.
This remitting–relapsing model is characterized by the appearance
of an ascending paralysis. First, we validated expression of our ther-
apeutic target at the peak of clinical score (reached 13 days after
immunization). Indeed, Plexin-A1 mRNA is significantly more
expressed in EAE mice compared to sham mice (Fig 9A). We next
investigated the therapeutic potential of MTP-PlexA1 on the evolu-
tion of clinical scores and at the histological level with spinal cord
myelin staining. Mice treated with vehicle only displayed first clini-
cal signs 10 days after immunization. Then mean clinical score
described a bell shape evolution with a maximum at day 13. Non-
linear regression showed that mean clinical score of mice treated
from day 1 with 1 lg/kg MTP-PlexA1 was significantly lower
compared to mice treated with vehicle (Fig 9B). This effect trans-
lated into a marked improvement of the myelin content at the
lumbar spinal cord level in treated animals (Fig 9C). The Fluo-
romyelin analysis of the dorsal region showed +48% signal
(P = 0.0124) and +41% in the lateroventral region (P = 0.0448;
vehicle group n = 3; MTP-PlexA1 n = 3 for a total of 21 microscopy
A
B
Figure 7. Rescue of corpus callosum myelination after cuprizone-induced demyelination.
Mice received 4-week cuprizone diet followed by 4-week normal diet with concomitant vehicle or MTP-PlexA1 injections.
A Microphotographs showing the corpus callosum of mice fed with cuprizone and stained with Luxol fast blue, PLP and Fluoromyelin to visualize demyelination. Scale
bar = 1 mm. White dot lines delineate the corpus callosum. Quantification of Luxol fast blue staining intensity is expressed as a percentage of healthy control (data
are presented as mean  SEM, vehicle n = 5, MTP-PlexA1 n = 4; Mann–Whitney test, *P = 0.0159).
B Proximity ligation assay analysis was performed to quantify NRP1/Plexin-A1 interactions per cells at the level of the corpus callosum. Representative
microphotographs are presented. (data are presented as mean  SEM, n = 9 microscopy fields of two representative vehicle-treated animals and five microscopy
fields of two representative MTP-PlexA1-treated animals, Mann–Whitney test, **P = 0.0027). Scale bar = 15 lm.
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fields; Fig 9D). Moreover, the clinical scores of mice treated with
10 lg/kg MTP-PlexA1 were significantly improved compared to the
1 lg/kg condition. Hence, we challenged in a second experiment
the therapeutic potential of MTP-PlexA1 when the treatment was
administrated after first clinical symptoms appeared (in this case at
day 10) and prolonged up to relapse phase. Strikingly, MTP-PlexA1-
treated mice display no relapse in the next 28 days, whereas 28.6%
of vehicle-treated mice display relapse with score ≥ 2 (see
Appendix Fig S3). Importantly, the administration of MTP-PlexA1
had no impact on the inflammatory level as seen by the similar
levels of circulating TNF-a measured by ELISA in all conditions at
day 11 (Fig 9E).
Discussion
Our expression data showed the expression of Plexin-A1 in mouse
and human oligodendrocytes. This expression is higher in patients
with MS compared to healthy controls. The in vitro studies demon-
strated the capacity of MTP-PlexA1 to counteract Sema3A inhibitory
effects on oligodendrocytes migration and differentiation. In vivo
studies showed that administrations of MTP-PlexA1 every 3 days at
the dose of 1 lg/kg induced beneficial therapeutic effects exempli-
fied by myelin integrity signal recovery in DTI-MRI longitudinal
follow-up of animals presenting cuprizone-induced demyelination.
Histological examination of the brains at the end of the protocol
showed complete restoration of myelin content in MTP-PlexA1-
treated animals compared to only partial recovery in vehicle-treated
animals. This myelin recovery is consistent with the functional
recovery observed for MTP-PlexA1-treated animals for which five
independent parameters of gait efficiency were measured. Such a
protective effect was also observed in the EAE model in which we
found that MTP-PlexA1 had a positive impact on the myelin content
of lumbar spinal cord. Hence, behavioural studies combined with
blood analysis demonstrated the innocuity of the MTP-PlexA1
peptides at the cognitive and biological levels.
Several studies indicate that Semaphorins play a role in OPC
migration and OL process outgrowth (Piaton et al, 2009). Our
results demonstrate that Plexin-A1, one of the major signalling
receptors of Sema3A (Tamagnone et al, 1999; Tamagnone & Como-
glio, 2000), is expressed in CNP-positive OL and overexpressed in
case of induced demyelination. We also show that a Sema3A/
Plexin-A1 signalling event triggers the inhibition of OL migration
and differentiation.
Neuropilins and CRMPs are key components of class 3 Sema-
phorin signalling in OPC and OL (Ricard et al, 2000, 2001; Cohen,
2005). Other members of the Plexin family have also been suggested
to act as regulators of Semaphorin signalling in OL. This is the case
of Plexin B1 for the transduction of Sema4D (Moreau-Fauvarque
et al, 2003) and that of Plexin A4 in OPC (Okada et al, 2007). More-
over, Sema4D-plexin-B1 interactions are critical for the pathogenesis
Figure 8. Analysis of the functional recovery with CatWalk assay.
Gait analysis of mice fed 6 weeks with cuprizone diet then receiving a curative
treatment with MTP-PlexA1 or vehicle during additional 4 weeks of normal diet.
All parameters are expressed relatively to the end of cuprizone treatment
(representing the last time without deficits). Statistical significance is calculated
towards values measured at the beginning of the experiment t0.
A Temporal parameters (data are presented as mean  SEM, n = 5 per
group; Mann–Whitney, STAND, *P = 0.028, SWING, *P = 0.028, STEP CYCLE,
*P = 0.0127).
B Kinetic and spatial parameters (data are presented as mean  SEM, n = 5
per group; Mann–Whitney, *P = 0.028).
A
B
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of EAE (Okuno et al, 2010). Our data now show that Plexin-A1
expression spatially and temporally fits with a role for Sema3A
signal transduction in OL. Plexin-A1 expression significantly
increased when provoking cuprizone-induced demyelination–
remyelination process. In this situation, Plexin-A1 expression was
only detected during the phase of acute demyelination during which
we also found transient expression of Sema3A in the lesion sites
mirroring what was previously shown in MS human samples (Wil-
liams et al, 2007), predominantly in the posterior third of the corpus
callosum. This strongly supported a role of Plexin-A1 in the
transduction of the Sema3A-induced migratory inhibition prevent-
ing remyelination. Indeed, we found in vitro that the silencing of
Plexin-A1 using RNAi or the blockade with an antagonist peptide
abolished the Sema3A-induced inhibition of OL migration. Interest-
ingly, the inhibitory effect of Sema3A on OPC differentiation was
also counteracted when blocking Plexin-A1. This suggests that the
beneficial effect seen in vivo with MTP-PlexA1 is related both on a
pro-migratory effect and on a differentiation effect.
To block Plexin-A1, we have used a synthetic peptide mimicking
its transmembrane domain. This type of antagonist previously
described for other targets such as NRP1 (Nasarre et al, 2010; Arpel
et al, 2016), HER2 (Arpel et al, 2016) or Eph-A2 (Sharonov et al,
2014) has been shown to act by the direct modulation of Plexin-A1
homodimerization or heterodimerization with Neuropilin-1. Long--
lasting effects were described on brain tumour growth when the
peptide was administrated every 3 days in vivo (Jacob et al, 2016).
We now observed therapeutic effects of MTP-PlexA1 in the demyeli-
nation models when administrated with the same schedule and
same dosage. While the exact fraction of peptide reaching the
lesions remains to be determined, the efficient protective effects
A B
C D
E
Figure 9. MTP-PlexA1 reduces EAE severity.
SJL female mice were immunized with PLP (+Pertussis toxin).
A Expression of Plexin-A1 was analysed in the whole brains of PLP-sensitized mice exhibiting a clinical score superior to 1.5 (EAE) and sham mice by RT–qPCR. GAPDH
was used as housekeeping gene to normalize gene expression (data are presented as mean  SEM, n = 5 per group, Mann–Whitney test, **P = 0.0079).
B Therapeutic treatment was administrated starting from day 1 (three times per week) consisting of vehicle alone, MTP-PlexA1 1 lg/kg or 10 lg/kg. Analysis of clinical
signs of the disease. Data are presented as mean  SEM, vehicle n = 6, MTP-PlexA1 (1lg/kg) n = 7, MTP-PlexA1 (10lg/kg) n = 7. Non-linear regressions (bell shape)
are plotted and used for statistical significance (vehicle/MTP-PlexA1 (1 lg/kg), *P < 0.0001; vehicle/MTP-PlexA1 (10 lg/kg), *P < 0.0001; MTP-PlexA1 (1 lg/kg)/MTP-
PlexA1 (10 lg/kg), *P = 0.0304).
C Fluoromyelin and DAPI stain of 6-lm lumbar sections prepared from three mice treated with either the vehicle and three mice treated with MTP-PlexA1 (1 lg/kg)
11 days postinjection. White star shows the localization of the high magnification. Yellow dot lines delineate the area analysed for myelin content. Scale bar = 100 lm.
D Fluoromyelin intensity analysis (data are presented as mean  SEM, 3 slices per animal, n = 3 in both groups; dorsal Fluoromyelin content, *P = 0.0336; lateroventral
Fluoromyelin content, *P = 0.0479; Mann–Whitney test).
E Inflammation status of mice determined by ELISA for TNF-a 11 days postimmunization (data are presented as mean  SEM, n = 4 in both groups; ns, Mann–Whitney test).
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observed in two different models of induced demyelination suggest
that the required therapeutic dose is in the range of lg/kg. A prox-
imity ligation assay indeed demonstrated a significant decrease in
NRP1/Plexin-A1 dimers in brain slices prepared from treated
animals. This assay confirmed a direct impact of MTP-PlexA1 on
the signalling of Plexin-A1 in the lesion sites. However, membrane
targeting peptides exhibit no specificity towards OL cells and Plexin-
A1 is also expressed in adult neurons. While previous studies in
cancer settings showed no obvious deleterious effects after 1-month
treatments, we performed here series of behavioural experiments to
challenge whether the peptide would or would not impair cognitive
functions in a context of chronic administration. We found no effect
on cognitive performance after 4-week treatments in three different
tests. This was also correlated with no sign of hematologic or meta-
bolic alteration. Thus, this antagonist peptide could be seen as an
interesting drug candidate in the MS context. A translation to
humans should be facilitated by the 100% homology between the
mouse and human Plexin-A1 transmembrane domain sequences.
Moreover, our comparative analysis of white matter from nine
healthy controls or 11 MS patients revealed a marked increase in
Plexin-A1 expression in MS. Future investigations will explore the
dynamic of Plexin-A1 expression along the disease evolution to
better identify the right therapeutic window while treating patients
with anti-inflammatory medications. Hence, because current treat-
ments of MS are essentially combating inflammation but are not
repairing lesions, future studies will address whether a combination
treatment associating anti-inflammatory molecules with Plexin-A1
antagonist creates all conditions for repairing MS lesions.
Materials and Methods
Cell culture
Oli-neu cells (Jung et al, 1995) kindly provided by Dr Trotter’s labora-
tory were cultured at 37°C, with 5% CO2, and expanded in Sato
medium containing 1% horse serum (DMEM, with 0.2% (w/v)
sodium bicarbonate, 0.01 mg/ml insulin, 0.01 mg/ml transferrin,
220 nM sodium selenite, 100 lM putrescine, 500 nM triiodothy-
ronine, 520 nM thyroxine and 200 nM progesterone). Migration
experiments were performed in Sato medium without progesterone,
triiodothyronine and thyroxine on surfaces coated with poly-L-lysine.
E15 embryos were collected from pregnant C57BL/6 mice for
brain dissection. Cells from cerebral hemispheres were mechanically
dissociated and grown in suspension as neurospheres in Neuro-
basal-A medium supplemented with 2 mM L-glutamine, 2% B27,
penicillin (100 U/ml), streptomycin (100 lg/ml), EGF (20 ng/ml)
and bFGF (20 ng/ml). Differentiation was induced by plating neuro-
spheres on poly-L-ornithine surface in Neurobasal-A medium
supplemented with 2% B27, penicillin (100 U/ml), streptomycin
(100 lg/ml), EGF (2 ng/ml), FGF (2 ng/ml), triiodothyronine
(12.5 ng/ml) and ascorbic acid (50 lM).
Peptide
We used as previously described (Jacob et al, 2016) the specific
Plexin-A1 antagonist peptide corresponding to the transmembrane
domain of Plexin-A1 (TLPAIVGIGGGGGLLLLVIVAVLIAYKRK, amino
acid T1240 to K1268 according to UniProt entry P70206). The peptide
(MTP-PlexA1) was synthetized and purified by Peptide Specialty
(Heidelberg, Germany) by automatic peptide synthesis (Fmoc chem-
istry). Peptide purity estimated by RP-HPLC was more than 92%
according to the manufacturer’s indication. The peptide was solubi-
lized in 72 mM LDS (lithium dodecyl sulphate) at a concentration of
1 mg/ml for stock solution and used at 107 M in vitro and adminis-
trated in vivo every 3 days at 1 lg/kg or 10 lg/kg.
RNA interference
siRNA oligo control (AllStars Negative Control) and siRNA targeting
mouse Plexin-A1 (Mm_Plxna1_5) were purchased from Qiagen and
transfected into Oli-neu cells with INTERFERin (Polyplus-transfec-
tion).
Cell migration assay
Migration of Oli-neu cells was performed in Transwell CIM-Plate 16
(8 lm pore size filter ACEA Biosciences, Inc.) with xCELLigence
RTCA DP Instrument (ACEA Biosciences Inc.). Cells were pre-incu-
bated 1 h with vehicle alone or MTP-PlexA1 (107 M). The 1 × 105
cells were seeded in the upper chamber with 150 ll of medium. The
bottom well contained 160 ll of medium supplemented with 2%
foetal bovine serum for chemoattraction and 20 ng/ml Sema3A puri-
fied as previously described (Treinys et al, 2014) for repulsion. Anal-
ysis was performed after 6 h of migration according to the
manufacturer’s instructions. Data are expressed as a percentage of
positive control migration, i.e. the migration of Oli-neu with 2%
serum and without Sema3A.
RNA analysis
Total EAE mouse brain RNA was extracted with TRIzol (Sigma)
and analysed by reverse transcription–PCR. cDNA was amplified
using the CFX Connect Real-Time PCR Detection System (Bio-
Rad). A mix was done using the TaqManTM Universal PCR Master
Mix (Applied Biosystems) and the specific probe for Plexin-A1
(probe ID: Mm00501110_m1, Thermo Fisher). For normalization
of gene expression, GAPDH (probe ID: Mm99999915_g1 Thermo
Fisher) was used as housekeeping gene. MBP expression was
analysed with SYBR Green Supermix (Bio-Rad) using following
primers: GCCTGTCCCTCAGCAGAT and GCCTCCGTAGC-
CAAATCC. The following programme was used: 95°C for 10 min,
followed by 40 cycles of 95°C for 30 s, and polymerization at
60°C for 1 min. MBP expression was monitored after 4 days of
differentiation in the presence of Sema3A with MTP-PlexA1 treat-
ment or vehicle.
Animal experimentation
All experiments were performed in accordance with the French
animal protection laws and were approved by the Animal Care
Committee of the University of Strasbourg (APAFIS number #8755-
2017011817246097 and #9374-201605111128746v2). We used
C57BL/6 female mice (Charles River Laboratories) for Cuprizone
study. SJL/J female mice used for EAE were purchased from
Janvier and Charles River. All mice were 8 weeks of age and fed
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in a controlled environment (25°C) with free access to food and
water and housed on a 12-h/12-h day/night cycle. Before any
behavioural test, mice were put in experimentation room 1 h
before every session to acclimatize to environmental conditions.
After each trial, experimental set-ups were cleaned with 70%
ethanol to eliminate odorant cues. All experiments were conducted
in blind conditions with regard to mice treatments. At the end of
protocols, mice were euthanized, and brains were collected for
histological examination.
Cuprizone-induced demyelination
Mice were housed in plastic cages pre-bedded corn (Innovive refer-
ence M-BTM-C8) with pre-filled acidified water bottle (Innovive
reference M-WB-300A). Mice were paired-housed (one control with
one treated), and cages were changed weekly. After 1 week of accli-
mation to environment, mice were fed ad libitum with a 0.3% cupri-
zone-containing diet (Safe Nutrition, E82220, Version 0373 A04)
changed three times per week. Cuprizone diet consumption (three
times a week) and body weight (once a week) were monitored
during the whole protocol. Intraperitoneal administration of vehicle
(LDS, 0.072 mM) or MTP-PlexA1 (1 lg/kg) was done three times
per week.
Animals (five mice per condition: vehicle vs. MTP-PlexA1)
subjected to DTI-MRI (Diffusion Tensor Imaging Magnetic Reso-
nance Imaging), toxicity tests and histology analysis received
4 weeks of cuprizone diet, and those evaluated for locomotion
recovery using the CatWalk system received 6 weeks of cuprizone
diet followed by 4 weeks of normal diet ad libitum. For DTI-MRI
experiments, animals received treatments (vehicle, MTP-PlexA1)
from day 0 (start of cuprizone diet) and were imaged every 2 or
4 weeks (note that one mouse died during acquisition in the treated
group at week 4). For CatWalk analysis (one session at t0, W4, W6,
W8 and W10), animals received treatments (vehicle, MTP-PlexA1)
for 4 weeks from the end of cuprizone diet (6 weeks).
Preparation of brain sections
Animals were deeply anaesthetized before intracardiac perfusion of
4% formaldehyde at 4°C. Brains were then removed and postfixed
in 4% (v/v) formaldehyde (FA) at 4°C for 2 h. After 24 h washing
in TBS, frontal vibratome sections (70 lm thick) were performed
and collected in TBS for immediate use or in Watson medium for
20°C conservation.
Induction and assessment of active experimental
autoimmune encephalomyelitis
SJL/J female mice (9 weeks old) were immunized with the kit
developed by Hooke laboratories (EK-2120). Emulsion of PLP139-
151 fragment (HSLGKWLGHPDKF) in CFA (complete Freund’s adju-
vant) was administered as four subcutaneous injections of 50 ll in
the flank according to the manufacturer’s protocol. Mice received
0.4 lg of pertussis toxin intraperitoneally on the day of immuniza-
tion. Sham mice received only pertussis toxin and CFA without PLP.
Clinical score was performed on 21 mice (vehicle n = 8; MTP-
PlexA1 n = 8 for 1 lg/kg and n = 5 for 10 lg/kg). EAE was
assessed clinically in blind conditions on a daily basis according to
the following criteria: 0, no disease; 1, decreased tail tone; 2,
impaired righting reflex and partial hind limb paresis; 3, complete
hind limb paralysis; 4, hind limb paralysis with partial forelimb
paralysis; and 5, moribund or dead. To evaluate myelin integrity,
we collected the spinal cord of three vehicle and three MTP-PlexA1
(1 lg/kg)-treated animals 11 days postimmunization. We also
collected sera to determine TNF-a concentration with an ELISA kit
(RD System MTA00B).
Immunostaining
For immunohistochemistry on the US Biomax tissue array
(BNC17011b SF40/41), we used adjacent tissue sections of 6 lm
thickness. Sections were deparaffinized with toluene, then boiled
with the antigen retrieval sodium citrate buffer (pH = 6) for 10 min.
Sections were incubated overnight at 4°C with primary antibodies
Plexin-A1 (ab23391, Abcam, 1:200), CNP (ab6319, Abcam, 1:500)
or PLP (homemade, 1:500). Slides were then incubated with biotiny-
lated secondary antibodies (Vector Laboratories, 1:200), amplified
with the ABC Elite Vectastain kit and developed with the DAB kit
from Vector Laboratories. Images of the two sections were false-
colour-coded and overlaid in order to exemplify double-stained cells
using ImageJ software.
Human cryosections of control and MS patients were prepared
from frozen tissue blocks of white matter. All samples were
obtained from the Netherlands Brain Bank, the Netherlands Institute
for Neuroscience, Amsterdam (open access: www.brainbank.nl). All
material has been collected from donors for or from whom a written
informed consent for a brain autopsy and the use of the material
and clinical information for research purposes had been obtained by
the NBB in accordance with the principles set out in the WMA
Declaration of Helsinki and the Department of Health and Human
Services Belmont Report. Cryosection were co-stained with the same
Plexin-A1 (1:200) and CNP (1:250) antibodies, before detection with
Cy3 anti-rabbit and A488 anti-mouse secondary antibodies (Jackson
ImmunoResearch, 1:300).
For Plexin-A1 expression study, brain sections were incubated
overnight at 4°C under agitation with anti-Plexin-A1 antibodies and
mouse anti-CNP antibodies before detection using Alexa488-conju-
gated anti-rabbit IgG and Cy3-conjugated anti-mouse IgG. The brain
sections (prepared from three animals) were then mounted in Vecta-
shield medium with DAPI. The percentage of Plexin-A1-positive
oligodendrocytes was determined on at least five frontal sections at
the level of the corpus callosum, the cortex and the striatum.
Figure 3A shows Plexin-A1 expression in the corpus callosum,
while quantification reflects averaged expression in the three brain
regions.
Western blot
Proteins were extracted in a PBS/Triton 1% buffer with protease
inhibitors (Sigma) using the Minilys system (Bertin). Proteins were
resolved in a 4–20% SDS–PAGE gel and transferred onto a nitrocel-
lulose membrane (Trans-Blot Turbo System, Bio-Rad). The blots
were soaked in blocking solution (TBS/0.1% Tween/5% milk) for
1 h at RT. Primary antibody (Plexin-A1 PA5-77697; Invitrogen,
1:1,000) was incubated overnight at 4°C. After several washes (three
times for 5 min, TBS/Tween 0.1%), secondary antibody (anti-rabbit
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HRP; Bio-Rad, 1:3,000) was incubated for 1 h at RT in TBS/1%
Tween/5% BSA. The revelation step was performed using Clarity
ECL Blotting Substrates (Bio-Rad) according to the manufacturer’s
instructions. Images of the immunoblots were acquired and anal-
ysed thanks to Chemidoc Touch Imaging System (Bio-Rad) and
normalized with the stain-free method.
Proximity ligation assay
Cells were seeded on Lab-Tek Permanox slides overnight, and then
treated with appropriate peptide 107 M for 1 h or transfected with
the appropriate siRNA for 48 h. After fixation with 1% PFA for
10 min, slices were permeabilized with PBS/0.1% Triton X-100.
Primary antibodies (NRP1 from Evitria, 1:500; and Plexin-A1 from
Abcam, ab23391, 1:200) were incubated overnight at 4°C in PBS.
The proximity ligation assay was then performed according to the
manufacturer’s recommendations with the “detection orange” kit
(Sigma). Quantification of the dots was performed using ImageJ
software.
Myelin staining
Plaques of demyelination (Matsushima & Morell, 2001) were
observed at the histological level by the mean of osmium tetroxide
(OsO4) impregnation.
For histological analysis, brains were fixed with 10% FA, dehy-
drated and embedded in paraffin. Sagittal slices of 6 lm were cut
with microtome. Luxol fast blue staining (Abcam) was performed
according to the manufacturer’s instructions. Images were collected
with Leica microscope (LEITZ DMRB; equipped with AxioCam
Zeiss) using ×1.6 objective. Images were processed with ImageJ
software (National Institutes of Health) as follows. Red channel was
extracted from RGB pictures and grey values inverted to get myelin
signal. For each slice, the relative Luxol fast blue staining intensity
was calculated by dividing the mean intensity measured in splenium
and adjacent half of corpus callosum body by the mean intensity
measured in cortex. Mean intensity of each brain was calculated
from at least three slices.
EAE spinal cord was stored in a 4% PFA solution overnight at
4°C and then placed in 15% sucrose–phosphate-buffered saline solu-
tion for 24 h before embedding in OCT (optimal cutting temperature
compound). Fluoromyelin staining (Invitrogen ref F34651 diluted at
1:200) and DAPI staining were performed on 10 lm coronal
cryosections of the lumbar region of the spinal cord. Slice images
were collected on Hamamatsu Nanozoomer S60 (FITC 80 ms, DAPI
8 ms). Fluoromyelin intensity was measured using ImageJ software.
Regions of interest were drawn manually, D region corresponds to
the dorsal part of the spinal cord and VL to ventrolateral (vehicle
n = 3; MTP-PlexA1 1 lg/kg n = 3; the analysis was performed on a
total of 24 microscopic fields).
For PLP detection, 6-lm paraffin sections were dewaxed,
unmasked with citrate buffer (Sigma) and incubated overnight with
anti-PLP antibody (PLP Lp6, 1:500), followed by incubation with a
biotinylated goat anti-rabbit antibody diluted at 1:200 for 1 h at
room temperature. After washing, slides were incubated with ABC
Vectastain amplification system (Vector Laboratories) and revealed
with DAB (Vector Laboratories). Counterstaining was performed
using haematoxylin (Sigma).
MRI recording
MRI examinations were performed on 7/30 Biospec System (Bruker
BioSpin, Ettlingen, Germany). Transmission was achieved with a
quadrature volume resonator (inner diameter 86 mm), and a standard
mice brain quadrature surface coil (~ 19 × 19 mm2) was used for
signal reception (Bruker BioSpin, Ettlingen, Germany). MRI experi-
ments were executed with ParaVision 6.0.1 software. T2-weighted
axial anatomical dataset was acquired using RARE sequence employed
using 39 contiguous slices with 0.3 mm thickness and an in-plane
resolution of 0.078 × 0.078 mm2. Remaining parameters were as
follows: matrix 256 × 256, TE = 26.5 ms, TR = 5 s, N avg = 6, RARE
factor = 8 and acquisition time: 16 min. DTI was performed using a
diffusion tensor spin-echo echo-planar imaging (DTI-SE-EPI) sequence
with the following parameters: four shots, N avg = 2, TR = 3 s,
TE = 31 ms, 30 directions, 6 b-values, Δ/d = 12/6 ms and 23 consecu-
tive slices with resolution = 0.1 × 0.1 × 0.5 mm3, acquisition time:
60 min. For MRI experiments, anaesthesia was induced with 2.0–
2.5% isoflurane. Then, animals were fixed in an animal cradle (Min-
erve, France) using a tooth bar and ear bars for stable positioning of
the head. During MRI experiments, the anaesthesia was maintained
with isoflurane to stabilize the breath frequency around 80–90 bpm.
Respiration was monitored using a pressure pad under the thorax.
MRI acquisitions were done at t0, W4, W6 and W8.
Image processing and analysis
The signal bias of T2WI induced by the surface coil was corrected
with N4 bias correction (Advanced Normalization Tools, ANTs).
Brains were automatically extracted and co-registered to a reference
using FSL tools: BET and FLIRT (FMRIB Software Library, Oxford,
UK). A set of regions of interest corresponding to corpus callosum
and ventricles was designed manually and applied T2WI to extract
the signal of the corpus callosum normalized by the signal of the
ventricles using ImageJ (NHI, USA).
After interscan drift correction, we used FSL (FMRIB Software
Library, Oxford, UK) to reconstruct DRAD maps as a readout of
myelin integrity. Then, individuals’ T2WI, volume without diffusion
gradient, was co-registered to a reference using FLIRT (FMRIB Soft-
ware Library, Oxford, UK) and the transformation matrix was
applied to the corresponding maps. A set of regions of interest corre-
sponding to corpus callosum was designed manually and applied on
all maps to extract values using ImageJ (NHI, USA).
To illustrate the myelin loss, we calculated the mean ratio of
DRAD signal at W8/DRAD signal at t0 for each group. Pixels exhibit-
ing ratio values > 1 (corresponding to demyelination) were selected
using a mask before false colour coding and overlaid on the raw
DRAD images (ImageJ FIJI).
CatWalk assay
Gait analysis was performed using the CatWalk XT Automated Gait
Analysis System (Noldus Technology Company) according to the
manufacturer’s instructions. Here are definitions of the parameter
studied:
(i) Stand (s) or Stance Phase is the duration in seconds of contact
of a paw with the glass plate. (ii) Swing (s) or Swing Phase is the
duration in seconds of no contact of a paw with the glass plate. (iii)
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Swing Speed is the speed (distance unit/second) of the paw during
Swing. Swing Speed = Stride Length/Swing. (iv) Stride Length is the
distance (in distance units) between successive placements of the
same paw. Calculation of Stride Length is based on the x-coordi-
nates of the centre of the paw print of two consecutive placements
of the same paw during Max contact and taking into account
Pythagoras’ theorem. (v) Step Cycle is the time in seconds between
two consecutive Initial Contacts of the same paw.
Values are expressed relatively to week 6 of the protocol corre-
sponding to the last time without measurable deficit. Statistical
significance is calculated by comparison with starting time of the
experiment (t0).
Elevated plus maze
The EPM has been used to assess anxiety in animals as proposed for
pharmacological agents (Walf & Frye, 2007). In brief, we used a
plus-cross-shaped apparatus, with two open arms and two arms
closed by walls linked by a central platform 50 cm above the floor.
Mice were individually put in the centre of the maze facing an open
arm to explore the maze for a duration of 10 min. The time spent in
the open arm, number of rearing, heading and stretch attend posture
were used as an anxiety index. All parameters were measured using
a Video Tracker software (Anymaze).
Open field
The locomotion of animals treated for 4 weeks with MTP-PlexA1 or
vehicle was determined in an open-field test where mice are placed
individually in a polyvinyl plastic square open field. Mice that were
freely moving and the travelled distance were measured using a
Video Tracker software (Anymaze).
Spatial recognition task
Mice were subjected to 10-min exploratory sessions in an open field
enriched with three different objects. Five minutes later, one object
was placed to the opposite side and the same mouse was introduced
in the open field for a second exploratory session. The discrimina-
tion index was determined as the ratio of the time spent to explore
the displaced object over the time spent to explore not displaced
objects.
Blood analysis
Blood analysis of eight mice (four vehicles and four treated) treated
three times per week during 4 weeks with MTP-PlexA1 (1 lg/kg) or
vehicle (0.072 mM) was conducted at the Clinical Chemistry and
Hematology Platform of Institut Clinique de la Souris (ICS, Stras-
bourg, France) according to their laboratory routines.
Statistical analysis
Graphs were produced in Prism 5 or 7 (GraphPad), and data are
presented as mean  SEM. Comparisons of one factor between two
groups were analysed by unpaired t-test for normal distribution or
Mann–Whitney test otherwise. Multiple comparisons were analysed
with ANOVA and appropriate postanalysis. Significance was
accepted for values where *P < 0.05, **P < 0.01 and ***P < 0.001.
The number of animals per group for in vivo experiments was deter-
mined using the LaMorte (Boston University Medical Center) sample
size calculation method with an anticipated effect of 30% with
a = 0.05 and a power of 0.95. Grubb test analysis was performed to
exclude significant outliers in an experimental group. Animals were
randomly assigned to experimental groups and assessed in blind
conditions with regard to treatments. For animal studies, only one
animal dying during the procedure (e.g. anaesthesia accident in the
group MTP-PlexA1 in DTI-MRI experiment described in Fig 3) was
excluded from the analysis. With the exception of Fig 2, variance is
similar between groups statistically compared. In this particular
Fig 2, we applied Welch’s correction.
Expanded View for this article is available online.
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The paper explained
Problem
There is currently no treatment to repair the myelin sheaths lost in
multiple sclerosis. This crucial step is, however, mandatory to expect
full recovery of patients benefitting from anti-inflammatory treat-
ments used to jugulate the progression of the disease. One strategy to
achieve remyelination is to counteract the inhibitory molecules accu-
mulated in the lesion sites, thereby preventing spontaneous remyeli-
nation by blocking the arrival of oligodendrocytes for repair.
Results
In this study, we show that counteracting the Sema3A inhibitory
molecular barrier by targeting its receptor Plexin-A1 favours remyeli-
nation. The use of a specific peptidic Plexin-A1 antagonist cancelled
the anti-migratory and anti-differentiation effects of Sema3A by
disrupting the heterodimer NRP1/Plexin-A1 required to trigger signal-
ling. In vivo, the chronic administration of the peptide was remarkably
tolerated and showed marked improvement in the myelin content
and locomotor functions in two different animal models of MS.
Impact
These results demonstrate that the disruption of the Sema3A repulsive
functions allows normal myelinating cells to exert their spontaneous
remyelinating capacity. This opens unprecedented therapeutic oppor-
tunity by combining this novel approach with anti-inflammatory
drugs to envision a possible curative therapeutic option.
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